Yeah I can get a 60% EBITDA margin too, but that was in the pcp. When I update the numbers and assumptions it drops a bit to the ~40% mark - and the decline in margin makes some sense as they are saying that they are keeping their COVID testing capability ramped up "just in case" which makes sense, but would elevate the cost base and chew into the margin.
Ann: Half Yearly Report and Accounts, page-7
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$25.86 |
Change
0.030(0.12%) |
Mkt cap ! $12.38B | |||
| Open | High | Low | Value | Volume |
| $26.04 | $26.07 | $25.60 | $16.16M | 626.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 49 | $25.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $25.87 | 991 | 17 |
View Market Depth
| Last trade - 15.30pm 11/07/2024 (20 minute delay) ? |
| SHL (ASX) Chart |